X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IBI302
Therapeutic Area: Ophthalmology Product Name: IBI302
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021
Details:
IBI302 has ability to inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation. The primary objective of the study is to evaluate the efficacy and safety of IBI302 in the treatment of nAMD.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
